New Large Study: Hydroxychloroquine Saves Lives of COVID-19 Patients

first_imgHydroxychloroquine cut the death rate significantly in sick patients hospitalized with COVID-19, without heart-related side-effects, according to a new study published by Henry Ford Health System. The large study involved 25-hundred patients and found 13% of those treated with hydroxychloroquine alone died compared with 26.4% not treated with hydroxychloroquine. The study was published in the peer-reviewed International Journal of Infectious Diseases. “The findings have been highly analyzed and peer-reviewed,” said Dr. Marcus Zervos, division head of Infectious Disease for Henry Ford Health System, who co-authored the study with Henry Ford epidemiologist Samia Arshad. “We attribute our findings that differ from other studies to early treatment, and part of a combination of interventions that were done in supportive care of patients, including careful cardiac monitoring. Our dosing also differed from other studies not showing a benefit of the drug. And other studies are either not peer reviewed, have limited numbers of patients, different patient populations or other differences from our patients.”Zervos said the potential for a surge in the fall or sooner, and infections continuing worldwide, show an urgency to identifying inexpensive and effective therapies and preventions.“We’re glad to add to the scientific knowledge base on the role and how best to use therapies as we work around the world to provide insight,” he said. “Considered in the context of current studies on the use of hydroxychloroquine for COVID-19, our results suggest that the drug may have an important role to play in reducing COVID-19 mortality.”The study also found those treated with azithromycin alone or a combination of hydroxychloroquine and azithromycin also fared slightly better than those not treated with the drugs, according to the Henry Ford data. The analysis found 22.4% of those treated only with azithromycin died, and 20.1% treated with a combination of azithromycin and hydroxychloroquine died, compared to 26.4% of patients dying who were not treated with either medication.“Our analysis shows that using hydroxychloroquine helped saves lives,” said neurosurgeon Dr. Steven Kalkanis, CEO, Henry Ford Medical Group and Senior Vice President and Chief Academic Officer of Henry Ford Health System. “As doctors and scientists, we look to the data for insight. And the data here is clear that there was benefit to using the drug as a treatment for sick, hospitalized patients.”last_img read more

Tough Big Ten play lies ahead for UW

first_imgThe Wisconsin women’s tennis team concluded their non-conference season on Saturday finishing with a record of 9-3 in non-conference play.The Badgers’ early season success included a sweep of all the Wisconsin schools on their schedule – Green Bay, Milwaukee and Marquette – and capped off the non-conference schedule with a 7-0 sweep of the University of Wisconsin-Whitewater.Head coach Brian Fleishman is happy with the way his team has started the year and hopes they can learn from their losses.“We competed well at times,” Fleishman said. “I think we let some opportunities slip away, but I think we learned from those matches that we didn’t take advantage of and I think we can become a better team from those losses.”With the non-conference schedule out of the way, the Badgers now set their sights on their Big Ten campaign that begins this weekend at Michigan.The Big Ten will prove to be a demanding test for UW featuring three teams – Michigan, Northwestern and Nebraska – in the top 25 of the ITA rankings this year and eight schools in the top 75.Fleishman appreciates just how strong the Big Ten is this season.“[The Big Ten] is a competitive conference this year,” Fleishman said. “It’s much deeper than it was last year. After Northwestern and Michigan, it’s kind of who’s going to play better on that given day.”The Big Ten holds two top-25 singles players in Emina Bektas from the University of Michigan and Kate Turvy from Northwestern University. Bektas has only lost one match in the season and has already beaten the No. 8 singles player in the country, Chelsey Gullickson from the University of Georgia, this year.The conference breaks into the rankings in doubles as well with Northwestern and Michigan both having a pair in the top 25.Wisconsin senior Angela Chupa is going into her third season of Big Ten play and understands that the Big Ten as a whole is improved from just a season ago.“[The Big Ten] is very competitive this year,” Chupa said. “Every team has gotten better. In the past there has been just a couple of dominant teams and everyone else, this year every team has a chance for an upset. We’re just going to beat up on each other.”Wisconsin has not had a winning season in Big Ten play under Fleishman’s four seasons but came dangerously close last year, earning a 5-5 mark against conference foes.The Badgers have only played one conference game this year against the University of Minnesota, which resulted in a 5-2 loss.Fleishman knew his team missed an opportunity to win the first conference match this year.“We let the Minnesota match slip away from us,” Fleishman said. “[Minnesota] is a much better team this year than they were last year and they played really well against us.”In the loss to the Gophers, freshman Sarah Loebel got her first taste of conference play, losing at the No. 3 singles spot. Loebel has a winning record this year in singles matches at 7-4 but admits that while her first Big Ten match was a little intimidating initially, she eventually enjoyed the challenge her first taste of conference play produced.“I was really nervous,” Loebel said. “But the match was really exciting, I thought. And I hope we get some good wins in the Big Ten.”Wisconsin hopes that their early season success will lead to continued success in the gauntlet that is the Big Ten conference.Chupa knows the matches are going to be tough but the only thing that she and her teammates can do is play as hard as they can and hope that they come out on top.“We will have to battle,” Chupa said. “A lot of these matches are going to be really tough. Whoever fights the hardest and wants it the most is going to come out on top. We can never give up, just keep fighting even if you are down because you can always turn it around.“We just need to have fun. That’s what it comes down to – when we are having fun, we play our best.”last_img read more

Barcelona star Neymar summoned to appear in fraud court case

first_imgBarcelona forward Neymar has been ordered to appear in a Spanish court next month as one of the defendants in a fraud case brought by Brazilian investment fund DIS.The firm alleges it was the victim when Barca signed the player, third in the latest Ballon d’Or poll, from Brazilian club Santos.A judge in Madrid, acting on a request from the state prosecutor, ordered Neymar, his parents, former Barca president Sandro Rosell, incumbent Josep Maria Bartomeu and two former Santos officials to present themselves on February 1 and 2.Javier Faus, a former Barca vice president, was called to appear as a witness.”The judge … believes that the prosecutor’s requests are ‘relevant, necessary and balanced’ for them to require an examination of the facts,” a court statement read.Neither Barcelona, Neymar or any of the other defendants could immediately be reached for comment. The club has said it acted “fully within the law” and rejected the accusations contained in the DIS suit.The fund, which owned 40 per cent of Neymar’s rights when he was at Santos, alleges it was paid far less than it was entitled to when the player agreed to join Barcelona in 2013.The complaint was the latest twist to a saga that has also led to Barca, Rosell and Bartomeu facing trial for tax fraud. Bartomeu was a vice president under Rosell when Neymar was signed in a complex deal involving multiple contracts.Bartomeu, Rosell, who resigned following the allegations, and the club have been accused of defrauding the tax office of some €13m (£9.77m). All three have denied any wrongdoing.Prosecutors have asked for a prison sentence of two years and three months for Bartomeu and seven-and-a-half years for Rosell, plus fines and payments of outstanding taxes totalling more than €60m. The tax probe was launched after a club member questioned the figures given for the Neymar deal. Barca initially said they paid €57.1m but later admitted the cost was nearer €100m.–last_img read more